Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Share
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
iO Finance Partners acquires Seneca Trade Finance in £40m deal
Electric school bus funds ‘flowing’ positive for Blue Bird, says Barclays
Packaging Corporation of America reports 38.7% increase in Q1 2025 net income
Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
View Options
Source link
iO Finance Partners acquires Seneca Trade Finance in £40m deal
Electric school bus funds ‘flowing’ positive for Blue Bird, says Barclays
Packaging Corporation of America reports 38.7% increase in Q1 2025 net income
Wall Street keeps warning of a ‘sell America’ trade. Here’s why.